Leukemia · 2016 · 39 citations · 21 references
MedicineHematologyPharmacologyCancer PharmacologyClinical PharmacologyHematologic OncologyAnticoagulant TherapyAnticoagulation TherapyAntiplatelet TherapyPlatelet ActivationPlatelet FunctionPlatelet PhysiologyAntiplatelet DrugsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsBtk InhibitorsChronic Lymphocytic Leukemia TherapySide Effect ProfileToxicity Grading CriteriaTyrosine Kinase Inhibition
Bleeding because of impaired platelet function is a major side effect of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation (RIPA) in 64 patients with chronic lymphocytic leukemia (CLL) under ibrutinib at 287 time points. Eighty-seven bleeding episodes in 39 patients were registered (85 Common Toxicity Criteria (CTC) grade 1 or 2, 2 CTC grade 3) during a median observation period of 10.9 months. At times of bleeding, RIPA values were significantly lower (14 vs 28 U; P<0.0001). RIPA was impaired in patients receiving concomitant antiplatelet therapy or anticoagulation (14 vs 25 U, P=0.005). A gradual decline of median RIPA values was observed with increasing bleeding severity. Importantly, no CTC grade 2 or 3 bleeding were observed with RIPA values of >36 U. Sequential monitoring indicated a decrease of RIPA values from a median of 17 to 9 U within 2 weeks after initiation of treatment as well as an increase above the critical threshold of 36 U within 7 days when ibrutinib was paused. Low RIPA values were similar during treatment with another BTK inhibitor, CC292. Quantitative assessment of platelet function is a practical tool to monitor bleeding tendency under BTK-inhibitor therapy.
21
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text